-
Legend Biotech Corporation to Establish Advanced R&D Center in Philadelphia for Next-Generation Cell Therapies
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading chimeric antigen receptor (CAR) T cell therapy specialist based in China, has announced plans to establish a state-of-the-art research and development center in Philadelphia, Pennsylvania. The new 31,000 sq. ft. facility, expected to open in the third quarter of 2025, will focus on…
-
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced last week the opening of a new life sciences incubator in Shanghai, named Bayer Co.Lab Shanghai. The incubator is located in the Shanghai Innovation (SH-INNO) Park within the Zhanghiang biopharma cluster and is part of…
-
Global Researchers Call for the Revival of the Human Genome Project to Advance Precision Medicine
•
A consortium of international researchers, spearheaded by a team from China’s gene sequencing giant BGI, has issued a call to action for the revival of the Human Genome Project (HGP) in a new iteration dubbed HGP2. The initiative aims to address the burgeoning challenges facing the advancement of precision medicine…
-
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
•
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed in a London Stock Exchange filing its intention to pursue legal action against China’s genomics powerhouse BGI and its affiliates. The company alleges that BGI’s newly launched nanopore-based sequencing platform infringes upon or misappropriates Oxford…
-
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
-
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
•
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…
-
US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition
•
The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by Chinese leader Deng Xiaoping and U.S. President Jimmy Carter, has reached its sunset with the Washington government allowing it to expire on August 27, 2024. This followed two sequential 6-month extensions in August 2023 and…
-
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
•
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the…
-
American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data
•
WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered that over a thousand patents registered by Chinese inventors have received financial support from the US Defense Department, NASA, and other federal agencies. The analysis, which reviewed data from the USPTO dating back to 2010,…
-
New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate
•
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement with global optical leader Zeiss, further strengthening their existing partnership. This collaboration will leverage the patented “Defocus Integrated Soft Contact (DISC) Technology for Myopia Management,” developed by Hong Kong Polytechnic University, to enhance Zeiss’ MyoCare…
-
HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China
•
HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the China National Intellectual Property Administration for its proprietary DNA editing system, CRISPR-Cas12i, also known as the Cas12Max system. The patent encompasses the hfCas12Max nuclease, which HuidaGene independently developed, as well as the broader CRISPR-Cas12i system…
-
Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership
•
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized a partnership with the University of Science, Malaysia (USM). The collaboration aims to enhance academic exchange and scientific translation efforts, among other initiatives. Financial details of the agreement were not disclosed. This strategic partnership builds…
-
Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration
•
Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with premier academic institutions and leading scientific research organizations. The incubator is designed to dismantle conventional silos and foster interdisciplinary collaboration among professionals, scholars, corporations, and financiers across the spectrum of “industry, academia, research, medicine, and…
-
CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab
•
China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University of Macau, marking a significant step in the biotech sector. The partnership, formalized with a signing ceremony at the Guangdong-Macao in-depth cooperation zone in Hengqin, aims to leverage the university’s cutting-edge research capabilities and CNBG’s…
-
CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine
•
CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration…
-
Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation
•
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park located in Beijing E-Town, during the Boao Forum for Asia. The initiative aims to establish a hub for high-energy innovation resources, support the development of high-value innovative products, and foster an efficient innovation ecosystem. Bio…
-
China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing
•
China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome Editing Research, establishing a framework to regulate such activities and ensure their responsible development. The guidelines place a stringent prohibition on germline editing, which involves genetic modifications that could be passed down to future generations.…
-
Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits
•
Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on the neurological and psychiatric effects of the obesity/type 2 diabetes (T2D) drug semaglutide, marketed as Ozempic and Wegovy. The first-of-its-kind study scrutinized the outcomes within a year of the first dose, focusing on T2D patients.…
-
Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery
•
Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in China, has entered into a strategic partnership with the Innovation Center of Yangtze River Delta, Zhejiang University. This high-capacity innovation platform is a joint initiative by Zhejiang University and Jiashan county in Jiaxing city of…
-
Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab
•
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a strategic partnership with Shanghai’s East China Normal University (ECNU). The collaboration aims to establish a state-of-the-art joint laboratory dedicated to advancing research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDCs). Furthermore, the…
-
Semaglutide Use Linked to Rare Eye Condition NAION in New Study
•
A recent study has identified a potential link between the use of GLP-1-targeted diabetes and anti-obesity drug semaglutide, marketed as Wegovy/Ozempic by Novo Nordisk, and a rare ophthalmic condition. Research published in JAMA Ophthalmology revealed that physicians at Harvard and Brigham and Women’s Hospital in Boston discovered an increased risk…
-
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial…
-
Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy
•
A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A research team led by Dr. Yin Hao from Shanghai Changzheng Hospital’s Organ Transplant Center has successfully treated a 59-year-old patient with a 25-year history of type 2 diabetes (T2D) using stem cell-derived autologous regenerative islet…
-
Profluent’s Neural Network Model Designs High-Efficiency CRISPR Gene-Editing System
•
Biotechnology company Profluent has announced a significant advancement in the field of gene editing with the successful use of a neural network model to design CRISPR systems. These newly designed systems have been experimentally shown to edit genes with high efficiency and accuracy. The lead candidate from this initiative is…
-
German Study Highlights Potential of Amgen’s Blinatumomab in Treating Rheumatoid Arthritis
•
Researchers from Germany’s University of Erlangen-Nuremberg have unveiled promising clinical data on the use of bispecific T cell engagers (BiTes) in combating B-cell mediated autoimmune diseases, such as rheumatoid arthritis (RA). The study, titled “Bispecific T cell engager therapy for refractory rheumatoid arthritis,” published in Nature Medicine in December 2023,…
-
Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research
•
Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research cooperation agreement with the Guangzhou Institute of Respiratory Health (GIRH). The partnership aims to collaborate on clinical studies focusing on the use of exosomes derived from mesenchymal stem cells (MSC exos) for the treatment of…
-
Shanghai’s 9th People’s Hospital Launches Groundbreaking Gene Therapy Trial for Congenital Deafness
•
In a medical first, Shanghai’s 9th People’s Hospital has initiated the world’s inaugural clinical trial for a gene-editing therapy targeting congenital deafness attributed to otoferlin (OTOF) gene mutations. The therapy, developed by HuidaGene Therapeutics Co., Ltd, represents a significant advance in the treatment of auditory neuropathy, a leading cause of…
-
Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development
•
The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a set of Measures designed to “Support the High-Quality Development of Innovative Medicine in Beijing.” Released on April 7, 2024, these Measures are open for public feedback until April 9 and encompass a wide range of…
-
Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space, has entered into a strategic partnership with Hangzhou Medical College to establish a graduate education base focused on biology and medicine. This collaboration aims to create a conducive environment for the next generation of medical…
-
Chinese Scientists Discover Breakthrough Biodegradable Piezoelectric Material for Medical Implants
•
A team of Chinese scientists from Southeast University in Nanjing has made significant strides in the development of advanced materials for medical implants. Their research focuses on creating a transient implantable piezoelectric material that addresses the issues of biodegradability and brittleness commonly found in current options. These piezoelectric materials are…
-
China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology
•
The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9 gene editing technology, rejecting an invalidation challenge. The decision was announced by ERS Genomics Ltd, an Ireland-based company founded by Dr. Emmanuelle Charpentier, the Nobel prize-winning co-inventor of the technology, to manage and license access…
-
Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices
•
Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development of an implantable and bio-compatible Na-O2 battery. This innovation could significantly transform the landscape of implantable medical devices by potentially eliminating the need for frequent invasive surgeries to replace depleted batteries in devices like pacemakers…
-
CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment
•
The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences (CAS) in Hong Kong, has officially launched CARES Copilot 1.0, a cutting-edge chatbot powered by a large language model designed to assist medical professionals in diagnosis and treatment. CARES Copilot 1.0 integrates the vast knowledge…
-
China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates
•
China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the National Health Commission (NHC). The data, calculated in collaboration with the International Agency for Research on Cancer (IARC), aligns with the GLOBOCAN 2022 report. In 2022, China reported 4,824,700 new cancer cases, with a standard…
-
Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse
•
Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered into a strategic partnership with the College of Radiology at Shandong First Medical University. The collaboration aims to encompass several key initiatives: The duo will jointly construct China’s inaugural “Medical Imaging Metaverse Immersive Teaching and…
-
Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator
•
01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly established by China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; HKG: 2607; SPH), Shanghai Biopharmaceutical Frontier Industry Innovation Center Co., Ltd, a subsidiary of SPH, and the Hong Kong Science & Technology Parks Corporation (HKSTPC).…
-
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
•
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the launch of a new mammalian cell line construction technology platform named WuXiaADCC PLUS. This platform is designed to be an efficient, high-yield, and high Antibody Dependent Cell Mediated Cytotoxicity (ADCC) activity platform…
-
Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI
•
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing in artificial intelligence (AI), quantum mechanics, and molecular simulation algorithms, have announced a strategic partnership agreement. This collaboration aims to revolutionize the drug discovery process by combining cutting-edge AI capabilities with advanced molecular dynamics simulation.…
-
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
•
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into a partnership with Hutao Tech, a Beijing-based life science data specialist. The collaboration aims to combine Hutao’s market resources and industry expertise in life science data with Insilico’s AI drug development platform, Pharma AI, and…
-
Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a cooperation intention agreement with the United Arab Emirates’ Gulf Medical University. The collaboration aims to encompass talent exchange, channel construction, scientific research, and commercial translational research, among other areas. Financial details of the agreement have…
-
Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection
•
Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the development of an artificial intelligence (AI)-based model designed for the early detection of ovarian cancer. This cost-effective AI model aims to assist in diagnosing the deadliest form of gynecological cancer worldwide. In China, early-stage diagnosis…
-
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
•
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its Takeda Spark incubator program in China. Initially launched in 2021, the incubator program partners with consulting firms PricewaterhouseCoopers and Accenture, tech giant Amazon Web Services, and the investment fund Shanghai Biopharmaceutical Innovative Transformation Fund. Takeda…
-
AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies
•
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with local authorities and is proceeding to establish a research and development (R&D) center in Hong Kong, marking a significant step as it becomes the first leading global Big Pharma to do so in the city.…
-
XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization
•
XtalPi Inc., a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding (MOU) with the Advanced Biomedical Instrumentation Centre (ABIC) at the University of Hong Kong (UHK) to foster collaboration aimed at enhancing research and commercial applications of ABIC’s technological advancements both locally and internationally. Under the terms of…
-
China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development
•
China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of Decentralized Clinical Trials in Rare Disease Drug Clinical Research and Development,” open for public feedback for one month. The guidelines have been formulated by a research team that extensively reviewed the guidance and suggestions from…
-
University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University
•
The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established in collaboration with the United Nations’ (UN’s) International Vaccine Institute and Cambridge University. As reported by The South China Morning Post, the labs are anticipated to be operational by the second quarter of 2024 and…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
HKU and SIIDB Collaborate on Drug Development for Infectious Diseases
•
The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB) have entered into a Memorandum of Understanding (MoU) to collaborate on drug development. This strategic partnership aims to establish the United Research Center of Innovative Drugs for Major Infectious…
-
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
•
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic cooperation framework agreement with Hong Kong Science and Technology Parks Corp. The partnership aims to promote the establishment of a Contract Research, Development,…
-
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ Shanghai unit. The collaboration aims to develop a next-generation integrated antibody drug conjugate (ADC) platform technology, marking a significant step in the advancement of oncology treatments.…
-
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the launch of its innovative biotechnology patent platform, WuXiUI. Developed based on the ultra-enhanced flow plus cell culture process, this platform is designed to be suitable for mainstream cell lines and various molecular types, marking a…
-
Amgen Launches Global Collaboration Network to Advance Oncology Research
•
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its oncology team with eight prominent research centers across Australia, Canada, France, Germany, South Korea, Spain, and the United States. This initiative is designed to accelerate the development of new cancer treatments for conditions with unmet…
-
GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models
•
Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in mouse models, has entered into a partnership with Daxiang Biotech, a leading domestic company in the organoid-on-a-chip field. The collaboration aims to promote the technical integration of mouse models and organoids, with the goal of…
-
Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a strategic partnership with the National Medical Center for Infectious Disease/Beijing Ditan Hospital Capital Medical University. The collaboration will focus on the development of HIV drugs, encompassing various aspects of research and development. Collaborative Efforts in…
-
China Launches Unprecedented Multi-Center Hypertension Study with Global Implications
•
On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced in Beijing with the backing of China’s Ministry of Health (MOH) and Ministry of Science and Technology (MOST). This ambitious project is structured as a multi-center clinical trial, encompassing 150 clinical centers and engaging 13,000…
-
Ruijin Hospital Researchers Uncover Five New Mutations in Rare 17OHD Endocrine Disorder
•
In a significant advancement in endocrine research, scientists within the Endocrine Department at Ruijin Hospital have identified five novel mutations through clinical and genetic examinations of eight patients diagnosed with 17 alpha-Hydroxylase/17,20 Lyase Deficiency (17OHD). The most prevalent genotype observed was D487-F489del. Structural protein analysis and in vitro studies have…
-
Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study
•
In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17 alpha-Hydroxylase/17,20 Lyase Deficiency (17OHD), a rare inherited adrenal hyperplasia. The research, spanning three years and encompassing eight patients from seven families, unveiled six mutations within the CYP17A1 gene, with five being previously unreported. The D487-F489del…
